HIV潜伏：现有知识与未来方向。
HIV latency: present knowledge, future directions.
作者信息
Contreras Xavier, Lenasi Tina, Peterlin B Matija
机构信息
University of California San Francisco, 533 Parnassus avenue, Room U432, 94143, San Francisco, CA, USA.
出版信息
Future Virol. 2006;1(6):733-745. doi: 10.2217/17460794.1.6.733.
Abstract
Current therapies do not eradicate HIV from infected patients. Indeed, HIV hides in a latent form insensitive to these therapies. Thus, one priority is to purge these latent reservoirs. But what mechanisms are responsible for latency and what are the reservoirs of latently infected cells? The present knowledge in terms of HIV latency is still incomplete and current therapeutic strategies fail to eradicate completely latently infected cells. What could the future bring?
摘要
目前的治疗方法无法从感染患者体内根除艾滋病毒。事实上，艾滋病毒以一种对这些治疗不敏感的潜伏形式隐藏着。因此，一个首要任务是清除这些潜伏库。但是，导致潜伏的机制是什么，潜伏感染细胞的储存库又是什么？就艾滋病毒潜伏而言，目前的知识仍然不完整，当前的治疗策略也未能完全根除潜伏感染的细胞。未来会带来什么呢？
相似文献
1
HIV latency: present knowledge, future directions.
Future Virol. 2006;1(6):733-745. doi: 10.2217/17460794.1.6.733.
2
Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
mBio. 2018 Nov 13;9(6):e02158-18. doi: 10.1128/mBio.02158-18.
3
Host T Cell Dedifferentiation Effects Drive HIV-1 Latency Stability.
J Virol. 2022 Mar 9;96(5):e0197421. doi: 10.1128/jvi.01974-21. Epub 2022 Jan 12.
4
Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs.
Front Microbiol. 2020 Jan 24;10:3060. doi: 10.3389/fmicb.2019.03060. eCollection 2019.
5
HIV latency in the humanized BLT mouse.
J Virol. 2012 Jan;86(1):339-47. doi: 10.1128/JVI.06366-11. Epub 2011 Nov 9.
6
HIV reservoirs, latency, and reactivation: prospects for eradication.
Antiviral Res. 2010 Jan;85(1):286-94. doi: 10.1016/j.antiviral.2009.09.016. Epub 2009 Oct 4.
7
Barriers for HIV Cure: The Latent Reservoir.
AIDS Res Hum Retroviruses. 2018 Sep;34(9):739-759. doi: 10.1089/AID.2018.0118. Epub 2018 Aug 28.
8
Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.
Cell Mol Life Sci. 2019 Sep;76(18):3583-3600. doi: 10.1007/s00018-019-03156-8. Epub 2019 May 25.
9
Transcriptome profiles of latently- and reactivated HIV-1 infected primary CD4 T cells: A pooled data-analysis.
Front Immunol. 2022 Aug 26;13:915805. doi: 10.3389/fimmu.2022.915805. eCollection 2022.
10
Development of a Novel Primary Human Monocyte-Derived Macrophage Model To Study Reactivation of HIV-1 Transcription.
J Virol. 2021 Sep 9;95(19):e0022721. doi: 10.1128/JVI.00227-21.
引用本文的文献
1
PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread.
Nanoscale Res Lett. 2015 Dec;10(1):413. doi: 10.1186/s11671-015-1112-z. Epub 2015 Oct 22.
2
HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters.
Nucleic Acids Res. 2014 Apr;42(8):4962-71. doi: 10.1093/nar/gku168. Epub 2014 Mar 11.
3
Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.
J Biol Chem. 2013 May 17;288(20):14400-14407. doi: 10.1074/jbc.M113.464834. Epub 2013 Mar 28.
4
Fluctuations in Tat copy number when it counts the most: a possible mechanism to battle the HIV latency.
Theor Biol Med Model. 2013 Mar 5;10:16. doi: 10.1186/1742-4682-10-16.
5
Activation of LTRs from different human endogenous retrovirus (HERV) families by the HTLV-1 tax protein and T-cell activators.
Viruses. 2011 Nov;3(11):2146-59. doi: 10.3390/v3112146. Epub 2011 Nov 2.
6
New insights into the control of HIV-1 transcription: when Tat meets the 7SK snRNP and super elongation complex (SEC).
J Neuroimmune Pharmacol. 2011 Jun;6(2):260-8. doi: 10.1007/s11481-011-9267-6. Epub 2011 Mar 1.
7
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.
PLoS Pathog. 2010 Jun 10;6(6):e1000803. doi: 10.1371/journal.ppat.1000803.
8
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
J Biol Chem. 2009 Mar 13;284(11):6782-9. doi: 10.1074/jbc.M807898200. Epub 2009 Jan 9.
9
Transcriptional interference antagonizes proviral gene expression to promote HIV latency.
Cell Host Microbe. 2008 Aug 14;4(2):123-33. doi: 10.1016/j.chom.2008.05.016.
10
HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription.
PLoS Pathog. 2007 Oct 12;3(10):1459-69. doi: 10.1371/journal.ppat.0030146.
本文引用的文献
1
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.
Nature. 2006 Sep 21;443(7109):350-4. doi: 10.1038/nature05115. Epub 2006 Aug 20.
2
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
Nat Med. 2006 Oct;12(10):1198-202. doi: 10.1038/nm1482. Epub 2006 Aug 20.
3
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells.
PLoS Pathog. 2006 Jul;2(7):e68. doi: 10.1371/journal.ppat.0020068.
4
Retroviral DNA integration: viral and cellular determinants of target-site selection.
PLoS Pathog. 2006 Jun;2(6):e60. doi: 10.1371/journal.ppat.0020060. Epub 2006 Jun 23.
5
Are viral-encoded microRNAs mediating latent HIV-1 infection?
DNA Cell Biol. 2006 Apr;25(4):223-31. doi: 10.1089/dna.2006.25.223.
6
Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation.
J Virol. 2006 May;80(9):4570-9. doi: 10.1128/JVI.80.9.4570-4579.2006.
7
Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.
Neurology. 2006 Mar 28;66(6):919-21. doi: 10.1212/01.wnl.0000204294.28189.03. Epub 2006 Mar 1.
8
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
EMBO J. 2006 Jan 11;25(1):139-49. doi: 10.1038/sj.emboj.7600900. Epub 2005 Dec 1.
9
Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency.
Retrovirology. 2005 Nov 23;2:73. doi: 10.1186/1742-4690-2-73.
10
IL-7 as a potential therapy for HIV-1-infected individuals.
Expert Opin Biol Ther. 2005 Nov;5(11):1421-6. doi: 10.1517/14712598.5.11.1421.
Zotero 插件